Cabozantinib as a second-line treatment option in hepatocellular carcinoma

Alberto D’Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello

Research output: Contribution to journalReview article

1 Citation (Scopus)


Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor tyrosine kinases approved for renal cell carcinoma that could be useful also for the treatment of HCC. Areas covered: This review describes the chemical structure, the pharmacologic properties and current knowledge of the efficacy of cabozantinib in the treatment of HCC based on data available from first phase and later phase clinical trials. The ongoing studies testing cabozantinib, either alone or in combination with other drugs, are also described. Expert opinion: Despite the recent achievements in the use of cabozantinib for patients diagnosed with hepatocellular carcinoma, data are still needed to allow clinicians to make better decisions on how to treat specific patient subgroups.

Original languageEnglish
JournalExpert Review of Clinical Pharmacology
Early online date12 May 2020
Publication statusE-pub ahead of print - 12 May 2020


  • Cabozantinib
  • hepatocellular carcinoma
  • immunotherapy
  • liver dysfunction
  • population pharmacokinetics
  • precision medicine
  • second-line
  • toxicity
  • treatment
  • tyrosine kinase inhibitors (TKI)

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this